First-dose vaccine effectiveness against SARSCoV-2 infection in residents of Long-Term Care Facilities

Shrotri et al, The Vivaldi Study (26.03.21)

We conducted a systematic search for studies which evaluated SARS-CoV-2 vaccine effectiveness in residents of long-term care facilities (LTCFs) published between 01/01/2020 and 11/03/2021 … Our findings add to the growing body of evidence on the protective effect of the BNT162b vaccines in residents of LTCFs, and demonstrate the effectiveness of ChAdOx1 in this vulnerable population.

Evaluating single-dose vaccine efficacy has become increasingly important in light of extended dosing intervals that have been implemented in order to maximise vaccine coverage across high-risk groups. Further work is required to evaluate the effectiveness of the first vaccine dose after 8-12 weeks, as well as following the second dose, and to evaluate the long-term impact of vaccination on SARS-CoV-2 infection, transmission and mortality in LTCFs. This will inform policy decisions regarding the ongoing need for disease control measures in LTCF such as visitor restrictions, which continue to have a detrimental impact on the wellbeing of residents, their relatives, and staff.